share_log

HC Wainwright Reiterates "Buy" Rating for First Wave BioPharma (NASDAQ:FWBI)

HC Wainwright Reiterates "Buy" Rating for First Wave BioPharma (NASDAQ:FWBI)

HC Wainwright 重申第一波生物制药（纳斯达克股票代码：FWBI）的 “买入” 评级
Defense World ·  2023/01/28 03:32

First Wave BioPharma (NASDAQ:FWBI – Get Rating)'s stock had its "buy" rating restated by research analysts at HC Wainwright in a research report issued to clients and investors on Thursday, Benzinga reports. They currently have a $18.00 target price on the stock. HC Wainwright's price objective would indicate a potential upside of 231.49% from the stock's current price.

First Wave BioPharma（纳斯达克：FWBI — 获取评级）Benzinga报道，HC Wainwright的研究分析师在周四向客户和投资者发布的研究报告中重申了该股的 “买入” 评级。他们目前的股票目标价格为18.00美元。HC Wainwright的价格目标将表明该股的当前价格可能上涨231.49％。

First Wave BioPharma Stock Performance

第一波生物制药股票表现

FWBI stock opened at $5.43 on Thursday. The business has a 50 day moving average price of $1.40 and a 200 day moving average price of $2.98. First Wave BioPharma has a fifty-two week low of $3.01 and a fifty-two week high of $348.60.

FWBI股票周四开盘价为5.43美元。该公司的50天移动平均价格为1.40美元，200天移动平均线价格为2.98美元。First Wave BioPharma创下五十二周低点3.01美元，五十二周高点为348.60美元。

Get
获取
First Wave BioPharma
第一波生物制药
alerts:
警报：

First Wave BioPharma (NASDAQ:FWBI – Get Rating) last posted its earnings results on Monday, November 14th. The company reported $2.60 earnings per share for the quarter, topping the consensus estimate of ($3.01) by $5.61. Analysts forecast that First Wave BioPharma will post -43.53 EPS for the current fiscal year.

First Wave BioPharma（纳斯达克股票代码：FWBI — Get Rating）最后一次公布财报是在11月14日星期一。该公司公布了本季度每股收益2.60美元，比市场普遍预期的3.01美元（3.01美元）高出5.61美元。分析师预测，First Wave BioPharma将在本财年公布每股收益为-43.53。

Institutional Investors Weigh In On First Wave BioPharma

机构投资者关注第一波生物制药

An institutional investor recently raised its position in First Wave BioPharma stock. State Street Corp boosted its position in shares of First Wave BioPharma, Inc. (NASDAQ:FWBI – Get Rating) by 97.4% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 82,593 shares of the company's stock after buying an additional 40,755 shares during the period. State Street Corp owned 6.02% of First Wave BioPharma worth $122,000 as of its most recent SEC filing. Institutional investors own 1.98% of the company's stock.
一位机构投资者最近提高了其在First Wave BioPharma股票中的头寸。根据State Street Corp在向美国证券交易委员会发布的最新披露中，State Street Corp在第三季度将其在First Wave BioPharma, Inc.（纳斯达克股票代码：FWBI — Get Rating）的股票头寸提高了97.4％。该公司在此期间又购买了40,755股股票后，拥有该公司82,593股股票。截至美国证券交易委员会最近提交的文件，State Street Corp拥有First Wave BioPharma6.02％的股份，价值12.2万美元。机构投资者拥有该公司1.98％的股票。

First Wave BioPharma Company Profile

第一波生物制药公司简介

(Get Rating)

（获取评分）

First Wave BioPharma, Inc, a clinical-stage biopharmaceutical company, engages in the research and development of targeted and non-systemic therapies for the treatment of patients with gastrointestinal diseases. Its product candidates include niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties; and the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients.

First Wave BioPharma, Inc是一家临床阶段的生物制药公司，从事用于治疗胃肠道疾病患者的靶向和非系统疗法的研究和开发。其候选产品包括氯硝柳胺，一种具有抗病毒和抗炎特性的口服小分子；以及生物阿德鲁利酶，一种旨在消化脂肪和其他营养素的重组脂肪酶。

Featured Articles

精选文章

  • Get a free copy of the StockNews.com research report on First Wave BioPharma (FWBI)
  • MarketBeat Week in Review – 1/23- 1/27
  • Why Lucid Spiked Nearly 100% In One Day
  • Ride These Railroad Stocks for Growth and Income
  • ASML Sees Demand For Chips Rallying This Year, Boosts Sales View
  • KLA Corporation: Strength In A Troubled Semi-Market
  • 免费获取 StockNews.com 关于 First Wave BioPharma（FWBI）的研究报告的副本
  • MarketBeat Week 回顾 — 1/23-1/27
  • 为什么 Lucid 在一天之内飙升了近 100%
  • 利用这些铁路股票实现增长和收入
  • ASML 预计今年对芯片的需求将上涨，提振了销售前景
  • KLA 公司：在陷入困境的半市场中的实力

Receive News & Ratings for First Wave BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for First Wave BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.

接收《第一波生物制药日报》的新闻和评级 -在下面输入您的电子邮件地址，通过Marketbeat.com的免费每日电子邮件时事通讯接收First Wave BioPharma及相关公司的最新新闻和分析师评级的简明每日摘要。

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发